Wingor Bio在初始融资中获得数千万资金，本轮融资仍未结束；继续推进干细胞药物和临床项目-动脉网

Wingor Bio Lands Tens of Millions in Initial Funding with Round Still Open; Forges Ahead on Stem Cell Drug and Clinical Programs

CISION 等信源发布 2025-08-25 18:32



可切换为仅中文







SHENZHEN, China

中国深圳

，

Aug. 25, 2025

2025年8月25日

/PRNewswire/ --

Shenzhen Wingor Biotechnology Co., Ltd.

深圳市盈谷生物科技有限公司

(hereinafter 'Wingor Biotechnology')

（以下简称“ Wingor 生物科技”）

, a leading Chinese company in stem-cell and gene therapy,

，一家在干细胞和基因治疗领域领先的中国公司，

is pleased to announce significant progress in a financing round, raising dozens of millions in CNY.

很高兴地宣布在一轮融资中取得了重大进展，筹集了数亿元人民币。

This round of financing is led by KC Eternium Management, an affiliate of Globelink Holding investing as a strategic investor specializing in biopharmaceuticals and the integration of overseas resources.

本轮融资由环球控股旗下专注生物医药及海外资源整合的战略投资者KC Eternium Management领投。

KC Eternium Management's Chief Investment Officer,

KC Eternium Management的首席投资官，

Kent Cai

蔡肯特

, commented:

，评论道：

'We believe that Wingor Biotechnology is a representative enterprise with strong verticalized capabilities from leading technologies and research to production and commercialization capabilities. Through this collaboration, we hope to support Wingor's rapid development and empower deep international cooperations through exporting Wingor's leading treatments globally and accelerating the commercialization pathways for key pipelines through collaborative international clinical trial processes.'.

“我们认为，Wingor生物技术公司是一家具有强大垂直化能力的代表性企业，从领先的技术和研发到生产和商业化能力均表现出色。通过此次合作，我们希望能够支持Wingor的快速发展，并通过将其领先的治疗方法推广至全球，以及通过协作的国际临床试验流程加速关键产品管线的商业化路径，来推动深层次的国际合作。”

Stem-cell therapy represents a

干细胞疗法代表了一种

pioneering frontier in regenerative medicine

再生医学的先锋前沿

, enabling the repair and regeneration of damaged tissues at a cellular level – a breakthrough that has revolutionized treatment approaches for conditions once deemed incurable. Key benefits include offering personalized and targeted therapies with potentially fewer side effects than traditional methods, accelerating recovery times, and paving the way for cures in areas like neurodegenerative diseases, autoimmune disorders, chronic conditions such as diabetes, Parkinson's disease, spinal cord injuries, and organ failure.

，能够在细胞层面上修复和再生受损组织——这一突破性进展革新了曾经被认为无法治愈的疾病的治疗方式。其主要优势包括提供个性化和针对性的治疗，可能比传统方法产生更少的副作用，加速康复时间，并为神经退行性疾病、自身免疫性疾病、糖尿病、帕金森病、脊髓损伤和器官衰竭等领域的治愈带来希望。

。

Globally, demand for stem-cell treatments is surging, driven by aging populations, the rising prevalence of chronic illnesses

全球范围内，由于人口老龄化和慢性疾病患病率的不断上升，人们对干细胞治疗的需求正在激增。

, and increasing accessibility through biotechnological innovations.

，并通过生物技术创新提高可及性。

With over 25 years of experience in building businesses internationally, Globelink Holding partners with high-quality Chinese enterprises to unlock global markets through strategic investments that provide access to top-down decision makers and seamless integration with strong local partners. Especially in the renewable energy and healthcare sectors, Globelink and affiliated partners have footprints across various continents bringing leading technologies and products to countries with need..

拥有25年以上的国际企业建设经验，Globelink控股与高质量的中国企业合作，通过战略投资解锁全球市场，这些投资使他们能够接触自上而下的决策者，并与强大的本地伙伴实现无缝整合。尤其是在可再生能源和医疗保健领域，Globelink及其关联合作伙伴遍布各大洲，将领先的技术和产品带到有需求的国家。

The current financing round remains open, and the company welcomes additional investors with synergistic capabilities to join in driving the development and value realization of leading cell therapy technologies at Wingor.

当前融资轮次仍然开放，公司欢迎具备协同能力的投资者加入，共同推动 Wingor 领先的细胞治疗技术的发展与价值实现。

Introduction of Wingor Biotechnology

温格生物技术介绍

Founded in 2013,

成立于2013年，

Wingor Biotechnology is a nationally renowned high-tech enterprise specializing in cell and gene therapy

无锡翼高生物科技有限公司是一家专业从事细胞和基因治疗的国内知名高新技术企业。

. The company focuses on the research, development, and application of innovative cell drugs, exosome therapy, and drug delivery technology. It has strategically positioned itself across

公司专注于创新细胞药物、外泌体治疗和药物递送技术的研究、开发和应用，并已进行了战略布局。

six major industry sectors: drug research and development, cell storage, cell CDMO, cell-based medical aesthetics, health management, and education (Wingor Education).

六大产业板块：药物研发、细胞存储、细胞CDMO、细胞医美、健康管理、教育（永庚教育）。

Wingor Biotechnology continues to expand the boundaries of biotechnology applications, aiming to create a closed-loop for the entire cell industry chain.

稳格生物不断拓展生物技术应用的边界，志在为整个细胞产业创造闭环。

The company has established a dual-track industrialization model combining innovative drug IND and investigator-initiated trials, achieving strategic synergy between broad coverage of indications and depth of research and development,

公司建立了创新药IND与研究者发起试验相结合的双轨制产业化模式，实现了广覆盖适应症与深度研发的战略协同，

with more than ten research and development pipelines

拥有超过十条研发管线

。

Among them, the stem cell platform leads in southern

其中，干细胞平台在南方领先

China

中国

in the number of IND applications accepted for four stem cell drugs.

在接受的四种干细胞药物的IND申请数量上。

The exosome platform has completed PCC screening for its first exosome-conjugated small nucleic acid drug. The immune cell platform is progressing clinical development of W-iNKT therapy targeting solid tumors. The gene engineering+ platform is exploring cross-platform technology integration through technical cooperation with .

外泌体平台已完成其首个外泌体偶联小核酸药物的PCC筛选。免疫细胞平台正在推进针对实体瘤的W-iNKT疗法的临床开发。基因工程+平台通过与开展技术合作，探索跨平台技术整合。

MIT

麻省理工学院

。

At the same time, the company has established long-term cooperative relationships with more than 60 top-tier hospitals in

同时，该公司与国内60多家顶级医院建立了长期合作关系。

China

中国

, collaborating with them to conduct more than ten cell therapy clinical research projects. Currently, four projects have been approved, and recruitment has begun. For example, the company participated as a cell supplier in the '14th Five-Year Plan' national key project, Special Project 1: Stem Cell Therapy for Liver Failure (Chinese People's Liberation Army General Hospital), etc..

与之合作开展了十余项细胞治疗临床研究项目，目前已有四个项目获得批准，并开始招募患者。例如，公司作为细胞提供方参与了“十四五”国家重点研发计划，专项一：干细胞治疗肝衰竭（中国人民解放军总医院）等项目。

In response to unmet clinical needs in areas such as neurological diseases and degenerative diseases, Wingor Biotechnology will continue to deepen its dual-drive strategy of 'independent innovation + clinical translation' through the collaborative efforts of its clinical network of top-tier hospitals and international application channels..

针对神经类疾病、退行性疾病等领域的临床未满足需求，稳格生物将持续通过其顶级医院临床网络与国际应用渠道的协同合作，不断深化“自主创新+临床转化”双轮驱动战略。

Wingor looks forward to working with more industry partners to jointly build a cell therapy ecosystem covering R&D, clinical trials, and commercialization, providing breakthrough treatment solutions that are accessible and curable for patients around the world.

Wingor期待与更多行业伙伴合作，共同打造覆盖研发、临床和商业化的细胞治疗生态圈，为全球患者提供可及、可治愈的突破性治疗方案。

Learn more at:

了解更多请访问：

www.wingor.net

SOURCE Wingor

来源：Wingor

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+

44万+